Daily Market Updates: Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Global Markets

Home›Global Markets›North America›Drug maker Rohto plans clinical trials in Hong Kong as…

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Reported · Written up by our desk · North America

Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...

← Newer storyEthena Explained: USDe, sUSDe, Rewards and Exit Routes Older story →Anthropic IPO enthralls India's uber-rich, but where are the shares?

More like this

Global MarketsChinese scientists found giant ‘chimneys’ in deep water that could alter submarine warfare

Global MarketsIndian royals carve new calling decades after losing their thrones

Global MarketsSam Altman makes surprise South Korea visit as OpenAI builds on chip partnerships

Global MarketsInfosys dividend 2026: Record date tomorrow | Know dividend payout, yield, history, returns

Global MarketsChicago wheat retreats toward 4-month low on Russian export outlook

Sources

SCMP EconomyDrug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Global Markets

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

More like this

Sources

Get the close, explained.